Tipo	Descripción	Euros
1.01	Authorisation and registration procedure of generics medicines for human use	8350.71
1.02	Epigrafe suprimido por el artículo 47,7 de la Ley 25/2009, de 22 de diciembre, de modificación de diversas leyes para su adopción a la Ley sobre el libre acceso a las actividades de servicios y su ejercicio	0.0
1.03	Authorisation and registration procedure of medicines for human use different to those included in sections 1.1	20529.17
1.04	Marketing authorisation holder transmission of medicines for human use	697.57
1.05	Modification of marketing authorisation of medicines for human use defined as “major variation” in Commission Regulation (EC) nº 1084/2003 of 3 June 2003	7051.73
1.06	Modification of marketing authorisation of medicines for human use defined as type IB in Commission Regulation (EC) nº 1084/2003 of 3 June 2003	1236.85
1.07	Modification of marketing authorisation of medicines for human use defined as type IA in Commission Regulation (EC) nº 1084/2003 of 3 June 2003	717.25
1.08	Renewal authorisation procedure of medicines for human use	2319.51
1.09	Annual simple declaration of intention to market a medicine for human use already authorised	119.01
1.10	Authorisation procedure for the “parallel import” of medicines for human use. Modification of marketing authorisation for the “parallel import” of medicines for human use	731.61
1.11	Modification of marketing authorisation of "parallel import” of medicines for human use	362.86
1.12	Renewal authorisation procedure for “parallel import” of medicines for human use	362.86
1.13	Issue of a European certificate of batch release for vaccines and blood products of human use when an analysis of a bulk and a medicine for human use is required	731.61
1.14	Issue of a European certificate of batch release for vaccines and blood products of human use when an analysis of a medicine for human use is required	362.86
1.15a	Periodic safety evaluation report of a medicine: a) Half-annual and annual	378.92
1.15b	Periodic safety evaluation report of a medicine: b) Triennial	2295.2